Protective effect of FK-506 in pig-to-rat islet xenotransplantation is abrogated by prednisolone

Song, Z.; Wennberg, Lars; Zhang, J; Sundberg, Berit; Bari, S; Groth, Carl G.; Korsgren, Olle

doi:10.1016/s0041-1345(00)01096-4

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The oral bioavailability of tacrolimus ranges from 5 to 67% (mean value of 27%), and its half-life ranges from 3.5 to 40.5 hours ( 165 ). Protocols with tacrolimus constantly evolve ( 166 ). In a pre-clinical study on pig-to-NHP islet xenotransplantation, tacrolimus was orally administered daily from day −3 to up to day 56 to achieve stable levels (3–6 ng/mL) ( 164 ).…”

Section: The Prevention Of Xenotransplantation Rejectionmentioning

confidence: 99%

Current status of xenotransplantation research and the strategies for preventing xenograft rejection

Zhou

Wang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Transplantation is often the last resort for end-stage organ failures, e.g., kidney, liver, heart, lung, and pancreas. The shortage of donor organs is the main limiting factor for successful transplantation in humans. Except living donations, other alternatives are needed, e.g., xenotransplantation of pig organs. However, immune rejection remains the major challenge to overcome in xenotransplantation. There are three different xenogeneic types of rejections, based on the responses and mechanisms involved. It includes hyperacute rejection (HAR), delayed xenograft rejection (DXR) and chronic rejection. DXR, sometimes involves acute humoral xenograft rejection (AHR) and cellular xenograft rejection (CXR), which cannot be strictly distinguished from each other in pathological process. In this review, we comprehensively discussed the mechanism of these immunological rejections and summarized the strategies for preventing them, such as generation of gene knock out donors by different genome editing tools and the use of immunosuppressive regimens. We also addressed organ-specific barriers and challenges needed to pave the way for clinical xenotransplantation. Taken together, this information will benefit the current immunological research in the field of xenotransplantation.

show abstract

Section: The Prevention Of Xenotransplantation Rejectionmentioning

confidence: 99%